Company intelligence / Profile preview

Emmaus Life Sciences, Inc.

Torrance, California, United Statesemmausmedical.com ↗

Ownership: Public · EMMA
Development stage: Commercial

Overview

Endari® (L-glutamine oral powder) has demonstrated efficacy in reducing acute complications of sickle cell disease in adults and children aged five years and older. It received FDA approval in the U.S. in July 2017 and has since been approved or authorized in several other countries. The company’s pilot trial of L-glutamine for diverticulosis showed promising preliminary results with improved colonic mucosa appearance after six months of treatment.[3][4][8] Preclinical programs are ongoing for anti-cancer therapies and regenerative medicine applications.[6]

Therapeutic areas: OtherGastroenterologyHematologyOncology
Modalities: Small molecules (L-glutamine oral powder)
Industry: Biotech

Drug pipeline

2 assets

glutamine

Approved

1 more asset in the full pipeline.

Request access →

Partnerships

APCER Life Sciences – pharmacovigilance partnerKainos Medicine – collaboration on preclinical development of an IRAK4 inhibitor as a potential anti-cancer drug

Financials

Market cap: $3.6M
Total revenue: $6.3M
Enterprise value: $31.3M

Beyond the preview

Go deeper on Emmaus Life Sciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emmaus Life Sciences, Inc..

Explore the full profile